Inventor · disambiguated record
Philip Anthony Harris
Also filed as: HARRIS PHILIP A · HARRIS PHILIP ANTHONY · HINKLE KEVIN
27 granted patents·14 pending applications·893 citations·filing 1998–2024
97Inventor score
Files withSMITHKLINE BEECHAM CORP15GLAXOSMITHKLINE IP DEV LTD10BOLOOR AMOGH2GLAXO WELLCOME INC2GLAXOSMITHKLINE LLC2
Top patents by PatentIndex Score
41 records- 0197US6369086B1Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitorsSMITHKLINE BEECHAM CORP·Filed 1999·Granted Apr 9, 2002·213 cites·18 claims
- 0296US9556152B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jan 31, 2017·29 cites·20 claims
- 0396US6815439B2Substituted aza-oxindole derivativesSMITHKLINE BEECHAM CORP·Filed 2003·Granted Nov 9, 2004·53 cites·23 claims
- 0496US6268391B1Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinasesGLAXO WELLCOME INC·Filed 1998·Granted Jul 31, 2001·238 cites·26 claims
- 0595US7105529B2Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effectsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Sep 12, 2006·64 cites·5 claims
- 0695US7105530B2Pyrimidineamines as angiogenesis modulatorsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Sep 12, 2006·72 cites·10 claims
- 0794US7262203B2Pyrimidineamines as angiogenesis modulatorsSMITHKLINE BEECHAM CORP·Filed 2006·Granted Aug 28, 2007·32 cites·50 claims
- 0891US8114885B2Chemical compoundsBOLOOR AMOGH·Filed 2007·Granted Feb 14, 2012·22 cites·19 claims
- 0989US7109209B2Pyrazolopyridines, process for their preparation and use as therapeutic compoundsSMITHKLINE BEECHAM CORP·Filed 2005·Granted Sep 19, 2006·8 cites·22 claims
- 1087US10933070B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Granted Mar 2, 2021·2 cites·4 claims
- 1187US6541503B2Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitorsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Apr 1, 2003·22 cites·17 claims
- 1286US10899716B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2020·Granted Jan 26, 2021·2 cites·2 claims
- 1385US10590085B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Mar 17, 2020·3 cites·31 claims
- 1485US7238813B2Chemical compoundsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Jul 3, 2007·20 cites·18 claims
- 1584US10292987B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Granted May 21, 2019·4 cites·10 claims
- 1684US6624171B1Substituted aza-oxindole derivativesSMITHKLINE BEECHAM CORP·Filed 2000·Granted Sep 23, 2003·13 cites·9 claims
- 1783US10940154B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Granted Mar 9, 2021·3 cites·4 claims
- 1883US7812022B22-pyrimidinyl pyrazolopyridine ErbB kinase inhibitorsGLAXOSMITHKLINE LLC·Filed 2005·Granted Oct 12, 2010·8 cites·15 claims
- 1981US7189712B21,3-Oxazole compounds for the treatment of cancerSMITHKLINE BEECHAM CORP·Filed 2003·Granted Mar 13, 2007·13 cites·5 claims
- 2079US7858626B2Pyrimidineamines as angiogenesis modulatorsGLAXOSMITHKLINE LLC·Filed 2007·Granted Dec 28, 2010·3 cites·20 claims
- 2179US6964977B2Oxindole derivativesSMITHKLINE BEECHAM CORP·Filed 2001·Granted Nov 15, 2005·10 cites·9 claims
- 2278US6387919B1Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitorsGLAXO WELLCOME INC·Filed 1998·Granted May 14, 2002·34 cites·13 claims
- 2377US7166597B2Fused pyrazole derivatives being protein kinase inhibitorsGLAXO GROUP LTD·Filed 2001·Granted Jan 23, 2007·13 cites·13 claims
- 2475US2023120185A1Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Application pending·0 cites
- 2572US7034030B2Pyralopyridines, process for their preparation and use as therapeutic compoundsSMITHKLINE BEECHAM CORP·Filed 2002·Granted Apr 25, 2006·6 cites·25 claims
- 2669US11485710B2Heterocyclic amides as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2021·Granted Nov 1, 2022·0 cites·30 claims
- 2769US7279473B2Pyrazolopyridazine derivativesSMITHKLINE BEECHAM CORP·Filed 2002·Granted Oct 9, 2007·5 cites·36 claims
- 2869US2010105712A1Chemical compoundsSMITHKLINE BEECHAM CORP·Filed 2009·Application pending·0 cites
- 2960US7163940B2Pyrazolopyridinyl pyrimidine therapeutic compoundsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Jan 16, 2007·1 cites·25 claims
- 3060US2024383875A1Benzimidazole Pyridine DerivativesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3157US2012277258A1Chemical CompoundsBOLOOR AMOGH·Filed 2012·Application pending·0 cites
- 3255US2007249600A1Chemical compoundsCHEUNG MUI·Filed 2007·Application pending·0 cites
- 3348US2007287721A1Pyrazolopyridinyl pyridineBOYD F LESLIE·Filed 2006·Application pending·0 cites
- 3448US2005282810A1Oxindole derivativesHARRIS PHILIP A·Filed 2005·Application pending·0 cites
- 3545US2023192676A1Heterocyclic Amides as Kinase InhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3644US2011190280A1Thiazole And Oxazole Kinase InhibitorsADJABENG GEORGE·Filed 2008·Application pending·0 cites
- 3742US2013053375A1Amino-quinolines as kinase inhibitorsBURY MICHAEL JONATHAN·Filed 2011·Application pending·0 cites
- 3842US2007142437A1Chemical compoundsBROWN MATTHEW L·Filed 2007·Application pending·0 cites
- 3941US2016060222A1Amino-quinolines as kinase inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Application pending·0 cites
- 4037US2005009845A1Thienopyrimidine compounds as protein tyrosine kinase inhibitorsFiled 2002·Application pending·0 cites
- 4134US2013018039A1Imidazolyl-imidazoles as kinase inhibitorsBODMER VERA Q·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Philip Anthony Harris files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →